- 0O14, 0QAH, MRK Ticker
- LSE, XETRA, NYSE, F Exchange
- 69,000 Employees
- 💊 Health Care Sector
- 👩🏻⚕ Pharmaceuticals Industry
- Kenneth C. Frazier CEO
Financial statements — Merck
The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Total Revenue |
|
48B | 47B | 42B | 40B | 40B |
| Cost Of Revenue |
|
15B | 14B | 14B | 13B | 14B |
| Gross Profit |
|
33B | 33B | 29B | 27B | 26B |
| Research and Development |
|
14B | 9.9B | 9.8B | 10B | 10B |
| Selling General and Admin |
|
10B | 11B | 10B | 9.8B | 9.8B |
| Operating Expense |
|
40B | 35B | 33B | 33B | 34B |
| Operating Income |
|
8.5B | 12B | 8.9B | 7.3B | 6B |
| Other Income Expense Net |
|
0 | 0 | 0 | 0 | 0 |
| EBIT |
|
8.5B | 12B | 8.9B | 7.4B | 6.1B |
| Interest Income |
|
770M | 620M | 430M | 370M | 370M |
| Pretax Income |
|
8.8B | 11B | 8.7B | 6.5B | 4.7B |
| Income Tax |
|
1.7B | 1.7B | 2.5B | 4.1B | 720M |
| Minority Interest |
|
15M | -66M | -27M | 24M | 21M |
| Net Income |
|
7.1B | 9.8B | 6.2B | 2.4B | 3.9B |
| Net Income Basic |
|
7.1B | 9.8B | 6.2B | 2.4B | 3.9B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Current cash |
|
8.1B | 10B | 8.9B | 8.5B | 14B |
| Short term investments |
|
5.5B | 4.3B | 4.5B | 4.3B | 4.4B |
| Receivables |
|
7.9B | 6.8B | 7.1B | 6.9B | 7B |
| Inventory |
|
6.3B | 6B | 5.4B | 5.1B | 4.9B |
| Other current assets |
|
5.5B | 4.3B | 4.5B | 4.3B | 4.4B |
| Current assets |
|
28B | 27B | 26B | 25B | 31B |
| Long term investments |
|
64B | 57B | 57B | 63B | 65B |
| Property plant equipment |
|
18B | 15B | 13B | 12B | 12B |
| Goodwill |
|
20B | 19B | 18B | 18B | 18B |
| Intangible assets |
|
15B | 14B | 11B | 14B | 17B |
| Other assets |
|
10B | 6.8B | 7.6B | 6.1B | 5.9B |
| Total assets |
|
92B | 84B | 83B | 88B | 95B |
| Accounts payable |
|
4.6B | 3.7B | 3.3B | 3.1B | 2.8B |
| Current long term debt |
|
6.4B | 3.6B | 5.3B | 3.1B | 570M |
| Other current liabilities |
|
16B | 15B | 14B | 12B | 14B |
| Total current liabilities |
|
27B | 22B | 22B | 19B | 17B |
| Long term debt |
|
25B | 23B | 20B | 21B | 24B |
| Other liabilities |
|
12B | 12B | 12B | 11B | 8.5B |
| Minority Interest |
|
87M | 94M | 180M | 230M | 220M |
| Total Liabilities |
|
66B | 58B | 56B | 54B | 55B |
| Common stock |
|
2.5B | 2.6B | 2.7B | 2.7B | 2.8B |
| Retained earning |
|
47B | 47B | 43B | 41B | 44B |
| Treasury stock |
|
-57B | -56B | -51B | -44B | -41B |
| Capital surplus |
|
• | • | • | • | • |
| Shareholder equity |
|
25B | 26B | 27B | 34B | 40B |
| Net tangible assets |
|
-9.5B | -7.7B | -3B | 1.9B | 4.6B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Net Income |
|
7.1B | 9.8B | 6.2B | 2.4B | 3.9B |
| Depreciation |
|
3.6B | 3.7B | 4.5B | 4.6B | 5.4B |
| Changes in receivables |
|
1.1B | -290M | 200M | -150M | 530M |
| Changes in inventories |
|
330M | 540M | 340M | 230M | 170M |
| Cash change |
|
-2.4B | 1.6B | 370M | -5.8B | 910M |
| Cash flow |
|
10B | 13B | 11B | 6.4B | 10B |
| Capital expenditures |
|
-4.7B | -3.5B | -2.6B | -1.9B | -1.6B |
| Investments |
|
• | • | • | • | • |
| Investing activity other |
|
• | • | • | • | • |
| Total investing cash flows |
|
-9.4B | -2.6B | 4.3B | 2.7B | -3.2B |
| Dividends paid |
|
• | • | • | • | • |
| Net borrowings |
|
18B | 12B | 12B | 12B | 6.1B |
| Other financing cash flows |
|
• | • | • | • | • |
| Cash flow financing |
|
-2.8B | -8.9B | -13B | -10B | -9B |
| Exchange rate effect |
|
• | • | • | • | • |
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.